Background: Ikaros, which is encoded by IKZF1, is a transcriptional factor that play a critical role in hematopoiesis. Somatic IKZF1 alterations are known to be involved in the pathogenesis of leukemia in human subjects. Recently, immunodeficiency caused by germline IKZF1 mutation has been described. Objective: We sought to describe the clinical and immunologic phenotypes of Japanese patients with heterozygous IKZF1 mutations.
Lymphopoiesis and hematopoiesis are controlled by numerous transcription and signaling factors, which act at distinct stages. Loss of activity of these factors results in developmental arrest and leukemic transformation. Ikaros, which is encoded by IKZF1, is an essential transcription factor broadly expressed in hematopoietic cells. 1, 2 In human subjects a critical role for Ikaros in B-cell development is well recognized. Somatic alterations in IKZF1 have been frequently observed in patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL), especially in patients with Philadelphia-positive (Ph 1 ) BCP-ALL, which represents more than 80% of cases. 3 Ikaros-null (Ikzf1 been reported with various degrees of abnormal lymphopoiesis/ hematopoiesis. Differential gene regulation by individual zinc finger (ZF)-containing proteins contributes to phenotypic heterogeneity. 6 Although functional analysis of mutant Ikaros was not comprehensively performed, an infant who died of congenital pancytopenia was reported to carry a constitutive heterozygous IKZF1 mutation. 7 As for the immune system, genome-wide association studies revealed a significant association between IKZF1 variants and systemic lupus erythematosus (SLE). 8 These findings suggest the possibility of an association between various phenotypes in human subjects and a germline IKZF1 mutation. Very recently, a series of 6 families with germline mutations in IKZF1 associated with common variable immunodeficiency reported low B-cell numbers. 9 The report described a progressive loss of B cells and serum immunoglobulins and a predisposition to BCP-ALL. The identified IKZF1 mutations revealed a lossof-function mutation in IKZF1, leading to impairment of its target sequence. This report clearly showed that an autosomal dominant heterozygous germline mutations in IKZF1 could be responsible for a novel immunodeficiency predominantly characterized by an antibody deficiency. However, an in-depth description of clinical manifestations, together with the effect of IKZF1 mutations on B-cell development and autoimmunity, remains to be elucidated.
Here we describe 9 patients from 6 families with heterozygous IKZF1 mutations. The patients are characterized by a defect in B cells, which is caused by aberrant development of common lymphoid precursors (CLPs). Notably, some patients have pancytopenia or autoimmune diseases, including immune thrombocytopenic purpura (ITP) and SLE.
METHODS

Study approval
Informed consent was obtained from patients or their parents. The study was conducted in accordance with the Helsinki Declaration and approved by the ethics boards of the University of Toyama and Tokyo Medical and Dental University.
Genetic analysis
For whole-exome sequencing (WES), exome capture was carried out with a SureSelect Human All Exon V5 Kit (Agilent Technologies, Santa Clara, Calif), and massively parallel sequencing was performed with a HiSeq 2000 platform (Illumina, San Diego, Calif) with 100-bp paired-end reads. Data were processed with an in house-constructed analysis pipeline (Genomon-exome: http://genomon.hgc.jp/exome/en/), which aligned the reads by using the Burrows-Wheeler aligner 0.5.8, counted variant allele numbers by using Samtools, and annotated genes by using ANNOVAR. Variant filtering steps are described in Table E1 in this article's Online Repository at www.jacionline. org. Sanger sequencing was performed to validate the results. The crystal structure of a C2H2 ZF protein (Protein Data Bank 1G2D) was produced by using Chimera.
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Flow cytometry
PBMCs were stained with fluorochrome-conjugated antibodies. Stained cells were analyzed with the BD LSRFortessa (BD Biosciences, San Jose, Calif), and data were processed with FlowJo software (Tree Star, Ashland, Ore). For lymphocyte phenotyping, mAbs were used to stain the cell surface and are listed in Table E2 in this article's Online Repository at www.jacionline.org. For intracellular forkhead box P3 staining, PBMCs were labeled with anti-CD4 (Miltenyi Biotec, Bergisch Gladbach, Germany) and CD25 (Dako, Tokyo, Japan). Then cells were fixed and permeabilized with a Fixation/Permeabilization Kit (eBioscience, San Diego, Calif), washed in permeabilization buffer (eBioscience), and stained with anti-forkhead box P3 (clone 259D/C7; BD PharMingen, San Diego, Calif). For T-cell receptor repertoire analysis, an IOTest Beta Mark TCR-Vb Repertoire Kit (Beckman Coulter, Brea, Calif) was used. Bone marrow-derived mononuclear cells were used for evaluation of hematopoiesis in bone marrow. Cells were stained with the mAbs listed in Table E2 and divided as follows:
), and megakaryocyte-erythroid progenitors
). For B-cell lineage analysis, cells were stained with anti-CD19 (Miltenyi Biotec), IgM (BD PharMingen) and VpreB (clone HSL96; BioLegend, San Diego, Calif) after fixation and permeabilization, as previously described. 12 
Immunoblot and electrophoresis mobility shift assay
The entire coding region of IKZF1 was amplified from wild-type (WT) cDNA by using primers containing EcoRI and XhoI restriction sites. PCR products and pcDNA3 vector (Invitrogen, Waltham, Mass) were digested with EcoRI and XhoI, and each fragment was ligated with the Quick Ligation Kit (New England Biolabs, Ipswich, Mass). The mutant Ikaros expression vectors were generated by means of site-directed mutagenesis. The plasmids containing WT or mutant IKZF1 genes were transfected into HEK293T cells by using Lipofectamine LTX Reagent (Thermo Fisher Scientific, Waltham, Mass), according to the manufacturer's protocol. At 24 hours after transfection, the cells were subjected to immunoblot analysis and nuclear extraction for the electrophoresis mobility shift assay (EMSA). We used NE-PER Nuclear and Cytoplasmic Extraction Regents (Thermo Fisher Scientific) for nuclear extraction. We incubated nuclear extract with 32 P-labeled (a-dATP) IK-bs4 probe (forward: 59-gtc aTG ACA GGG AAT ACA CAT TCC CAA AAG C-39 and reverse: 59-gtc aGC TTT TGG GAA TGT GTA TTC CCT GTC A-39), which contains a high-affinity Ikaros binding site. 13 We used anti-Ikaros antibody (ab26083; Abcam, Cambridge, United Kingdom) and anti-V5 antibody (Sigma-Aldrich, St Louis, Mo) for immunoblotting and the EMSA supershift assay. Primer sequences and PCR conditions are available on request.
Immunofluorescence staining NIH3T3 cells were plated at a density of 5 3 10 4 cells/mL in 6-well culture dishes with a cover glass. Twenty-four hours later, pcDNA3 vector (1.0 mg per plate for single-plasmid transfection or 1.5 mg per plate and 0.75 mg for each plasmid for cotransfection experiments) containing HA-tagged WT, C147R, N159S, R162Q, or Y210C alleles of IKZF1 and/or V5-tagged WT alleles of IKZF1 were introduced by means of lipofection with Lipofectamine 3000 Reagent, according to the manufacturer's guidelines (Invitrogen). Immunostaining was performed, as previously described.
14 Briefly, 24 hours after transfection, the cells were fixed in the presence of 4% paraformaldehyde (pH 7.4) for 15 minutes and permeabilized with PBS containing 0.5% NP-40 for 10 minutes. They were then blocked by means of incubation overnight with 10% goat serum in PBS in the presence of an anti-V5 mouse monoclonal antibody (1:200 dilution; Medical & Biological Laboratories, Nagoya, Japan) and/or an anti-HA rabbit polyclonal antibody (1:200 dilution; SigmaAldrich). Alexa Flour 594-conjugated goat anti-mouse IgG antibody (Invitrogen, Eugene, Ore) and/or Alexa Flour 488-conjugated goat anti-rabbit IgG antibody (Invitrogen) were used as secondary antibodies. Cell nuclei were stained with Hoechst 33342 (Invitrogen). Images were acquired with a BZ-9000 fluorescence microscope (Keyence, Osaka, Japan), with identical exposure times to optimize the comparisons.
PBMCs, which were not stimulated or stimulated with anti-CD3/CD28 activating Dynabeads (Life Technologies, Oslo, Norway) for 24 hours, were used for immunofluorescence staining by using standard methods. 15 Briefly, cytospin preparations were fixed with 4% paraformaldehyde, permeabilized with acetone, washed, and incubated with anti-Ikaros antibody (Abcam). 49-6-Diamidino-2-phenylindole (Vector Laboratories, Burlingame, Calif) was used for counterstaining. Slides were analyzed with a fluorescence microscope (FV10i; Olympus, Tokyo, Japan) equipped with Fluoview viewer and review station (Olympus).
Proliferation assays
PBMCs were labeled with carboxyfluorescein succinimidyl ester (3 mmol/L; eBioscience) for 5 minutes at room temperature and stimulated for 3 days with anti-CD3 and anti-CD28 antibodies (1, 0.3, or 0.1 mg/mL: BD PharMingen). Then cells were stained for CD4 and CD8 and analyzed by means of flow cytometry.
Splicing product analysis
PCR was performed with cDNA from PBMCs prepared by using SuperScript VILO (Invitrogen). PCR products, which included the entire coding region on IKZF1, were cloned with the TOPO TA cloning kit (Life Technologies), and independent clones were sequenced. Primers are listed in Table E3 in this article's Online Repository at www.jacionline.org.
RESULTS
Identification of heterozygous mutations in IKZF1
Initially, we identified heterozygous IKZF1 mutations in 3 families from a dysgammaglobulinemia cohort (Table I, Fig 1 , and see the Supplemental Note in this article's Online Repository at www.jacionline.org). A 7-year-old boy (A.1) had ITP and dysgammaglobulinemia with low B-cell counts at 5 years of age. Patient B.1, a 16-year-old girl, had recurrent sinopulmonary bacterial infections since 2 months of age and was treated with intravenous immunoglobulin. She also had a history of Pneumocystis jirovecii pneumonia. Patient D.III.1 was an 11-year-old boy who had bacterial pneumonia with agammaglobulinemia at 6 years of age and IgA vasculitis at 3 years of age. After excluding the diagnosis of dysgammaglobulinemia with known causes, we performed WES using DNA samples from patients and unaffected family members and identified ) with a history of ITP without dysgammaglobulinemia also had the same mutation at 68 years of age. These findings prompted us to examine the possibility that heterozygous IKZF1 mutations caused immunodeficiency with or without autoimmune diseases. We sequenced the IKZF1 coding exons in a family (C.I.1, C.II.1, and C.II.2) with hypogammaglobulinemia of autosomal dominant inheritance, and we identified a heterozygous p.R162W mutation in IKZF1. All 4 missense mutations described above were located within the ZF2-coding sequence. One missense mutation (p.C147R) was found and affected cysteine, which coordinates zinc conferred rigidity to the finger. Three missense mutations (p.N159S, p.R162W, and p.R162Q) were also identified to affect amino acids that interact with DNA, 16 suggesting a deleterious effect for maintaining the finger structure and DNA-binding activity (Fig 2) .
At the same time, we performed WES in a patient (E.II.1) from an autoimmune disease cohort and identified a heterozygous IKZF1 mutation in the exon 5 donor splice site (c.58911G>A). The patient, an 8-year-old boy, was given a diagnosis of SLE at 3 years of age. Although his serum immunoglobulin levels were high at diagnosis, he has since developed hypogammaglobulinemia. His asymptomatic mother (E.I.1) carried the same mutation at 37 years of age. This mutation caused numerous abnormal splicing events, including insertions, deletions, or both in various locations, which are predicted to severely impair the function of ZF2, ZF3, or ZF4 (Fig 3) .
Patient F.2, a 5-month-old boy, showed pancytopenia with extremely low B-cell counts just after birth. Sanger sequencing with DNA samples from whole blood and nails uncovered the reported mutation (p.Y210C). 6 His unaffected brother (F.1) had the same mutation at 2 years and 6 months of age, but DNA from whole blood of his parents revealed no mutation, suggesting germinal mosaicism. This missense mutation affected one of the essential residues for structural integrity in ZF4 (Fig 2, A) .
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Impaired DNA binding activity and diffuse nuclear localizations of Ikaros
We characterized the functional defects in mutant Ikaros by means of immunoblotting and EMSA with HEK293T cells transiently expressing WT or mutant Ikaros. As shown in Fig 4, A, the mutant Ikaros protein was expressed at the expected molecular weight of 63 kDa. We then analyzed the intrinsic DNA-binding ability of the Ikaros proteins using EMSA with the IK-bs4 probe that contained a high-affinity Ikaros binding site (Fig 4, B) . We observed DNA binding to the IK-bs4 sequence in WT Ikaros-expressing cells. The specificity of binding was confirmed by using a supershift assay (see Fig E2 in this article' s Online Repository at www.jacionline.org). In contrast, all Ikaros mutants, except for the Y210C mutant, were unable to bind DNA. Intriguingly, the Y210C Ikaros mutant showed weak residual binding to the target sequence, which is consistent with previous reports. 7, 9 Taken together, all of the IKZF1 mutations identified in the current study were loss-of-function mutations because of their inability to bind to DNA.
Localization of Ikaros to pericentromeric heterochromatin is important for its normal function in chromatin remodeling and regulation of gene expression. To investigate nuclear localization of WT or mutant Ikaros, we performed immunostaining with NIH3T3 cells transiently expressing WT and/or mutant IKZF1. Both HA-tagged and V5-tagged WT Ikaros localized the nucleus and showed the punctate staining pattern (Fig 4, C and D) . On the other hand, HA-tagged mutant Ikaros located the nucleus but showed abnormal diffuse nuclear localization (Fig 4, C) . We then investigated NIH3T3 cells coexpressing HA-tagged WT or mutant Ikaros and V5-tagged WT Ikaros (Fig 4, E) . All of the HA-tagged mutant Ikaros, as well as HA-tagged WT Ikaros, displayed the punctate staining pattern when they were coexpressed with V5-tagged WT Ikaros. Therefore, similar to the previous study, 9 abnormal diffuse nuclear localization in mutant Ikarosexpressing cells was corrected by coexpression with WT Ikaros. Interestingly, our study showed abnormal pericentromeric localization of Y210C Ikaros, whereas the previous study demonstrated a normal localization pattern of Y210C protein when expressed alone. 9 This difference might be influenced by the experimental procedure. Immunofluorescence microscopy with anti-Ikaros antibody was performed in cells from patients (see Fig E3 in this article' s Online Repository at www.jacionline.org). Lymphocytes from patients exhibited a punctate staining pattern of Ikaros in response to CD3/CD28 stimulation, as did those from healthy control subjects, which indicates localization to pericentromeric heterochromatin. These findings were consistent with the results of coexpression of WT and mutant Ikaros with NIH3T3 cells.
Impaired B-cell development
The recurrent observation of aberrant IKZF1 in patients with BCP-ALL suggested its critical role in B-cell development in human subjects. 5 Indeed, all symptomatic patients but patient D.I.1 had extremely low B-cell counts (Fig 5, A , and see Table E4 in 
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2 B cells) in patient B.1 also suggest abnormal B-cell development (Fig 5, C, and see Fig E4, A, in this article's Online Repository at www.jacionline.org). Notably, asymptomatic subjects had normal B-cell counts, suggesting an incomplete penetrance similar to that seen in patients with other dominantly inherited immunodeficiency diseases. 17, 18 The patients, except B.1 and F.2, had infantile-onset progressive hypogammaglobulinemia, and interestingly, normal B-cell counts were confirmed in early infancy (Fig 5, B , and see Fig E4, B and C). Autoantibodies were detected at the onset of autoimmune disease. Patient F.2, with affected ZF4 function, had a lack of B cells only just after birth (Fig 6, A) . His B cells spontaneously recovered, although he remained to have hypogammaglobulinemia. No somatic reversion in IKZF1 was identified in the purified B cells (data not shown). In mouse models B-cell counts were reduced to a various degree, or B-cell recovery was also described, suggesting a mechanism of compensation. 
Genetic analysis of heterozygous mutation in IKZF1. A, ZF2 and ZF4 sequences. Cysteine (C) and histidine (H) residues, which coordinate the zinc atom, are highlighted in red. The 21, 2, 3, and 6 positions, which are the DNA-interacting residues, are highlighted in blue. The 212, 23, and 4 positions, which are essential residues for structural integrity, are highlighted in yellow. B, Crystal structures of IKZF1 (yellow). C147, N159, and R162 are shown in red.
To investigate hematopoiesis, including B-cell development, we evaluated bone marrow cells from patients A.1 and D.III.1 (Fig 7) . These patients showed reduced HSC and CLP counts and increased LMPP counts. Relatively normal numbers of GMPs suggested increased generation from LMPPs. The B-cell lineage cell number was 10-fold lower in the patients than in healthy control subjects, and it most likely resulted from reduced CLP counts. this article's Online Repository at www.jacionline.org).
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Although Ikaros is essential for development from pro-B to pre-B cells in mice, 20 the relative frequencies of pre-B cells were normal in human subjects. In a previous study patients with IKZF1 mutation had normal numbers of CD138 1 plasma cells in bone marrow, which were lacking in a patient with common variable immunodeficiency. 9 However, we could not evaluate CD138 expression in the bone marrow samples.
Other hematologic abnormalities
Immunophenotyping revealed that all patients except patient D.I.1 had increased T-cell counts and that very patient except patient F.2 had increased CD8 1 T-cell counts (see Table E4 ), results that are consistent with a previous study. 9 T-cell maturation and function were heterogeneous, including reduced regulatory T-cell counts, skewed T-cell receptor repertoire, and increased T-cell receptor ab which were found in some patients with autoimmune diseases or primary immunodeficiencies mostly associated with autoimmunity (see Table E4 and Fig E6, A, in this article's Online Repository at www.jacionline.org). 21, 22 Lack of gd T cells and a lower threshold of T-cell proliferation were observed, which were also described in mice (see Fig E6, B) . 1, 6, 23 T cells from patient B.1, who had a history of Pneumocystis jirovecii pneumonia, exhibited a predominance of naive phenotype and a poor response to anti-CD3/CD28 antibody, which were different features from those of the other patients (see Table E4 and Fig E6, B) . Other hematologic abnormalities, including low natural killer cell activity, anemia, and thrombocytopenia, were observed in a small fraction of the patients. Patient F.2, with affected ZF4 function, had nonautoimmune pancytopenia, which required frequent red blood cell and platelet transfusion just after birth. The infant reported the same phenotype and underwent allogeneic hematopoietic stem cell transplantation (HSCT) early in life but died of multiorgan failure at 40 days after HSCT. 7 Notably, patient F.2, who planned to undergo HSCT, recovered from pancytopenia spontaneously in 1 month and has survived without HSCT (Fig 6, B) .
DISCUSSION
Here we described 9 patients from 6 families with heterozygous IKZF1 mutations. We identified 5 missense mutations and 1 splice site mutation in the IKZF1. Two missense mutations (p.R162Q and p.Y210C) were previously reported, 7,9 but 4 mutations (p.C147R, p.N159S, p.R162W, and c.58911G>A) were novel. Interestingly, the p.R162L mutation was described by Kuehn et al, 9 and p.R162 might be recurrently mutated in IKZF1. All but 1 patient presented with dysgammaglobulinemia accompanied by a decreased number of peripheral B cells. Despite this finding, 3 asymptomatic carriers were found to have a normal number of peripheral B cells. Intriguingly, 4 patients had autoimmune diseases, including ITP, IgA vasculitis, and SLE. In addition, nonautoimmune pancytopenia was observed in 1 patient. A germline mutation in IKZF1 was originally identified in an infant with pancytopenia and absence of B cells. 7 In addition, 29 patients from 6 unrelated families have been reported thus far. 9 However, the clinical manifestation of autoimmunity, which was only observed in 1 patient with ITP, was not a focus in the previous study. 9 The current study also demonstrated that the patients showed aberrant CLP development, probably causing a lack of peripheral B cells. Therefore our study expands our understanding of the features of autosomal dominant Ikaros deficiency. In this cohort 3 of 12 patients were asymptomatic, and the penetrance of this disease was 75% (9/12), which was similar to the value of 72% (21/29) in a previous study. 9 The rate might be unaffected by ethnic background.
Although Ikzf1 null/null mice exhibit various abnormal hematopoiesis, including a lack of B-lineage cells, Ikzf1 null/wt mice have normal lymphocyte development. 6, 20 In contrast, the identification of mutations in IKZF1 in B cell-deficient patients in this study, together with a previous report, provides genetic evidence for a heterozygous IKZF1 mutation causing dysgammaglobulinemia with or without autoimmune disease in human subjects. This observation is supported by heterozygous IKZF1 alterations in patients with BCP-ALL and, notably, the heterozygous p.N159S and p.R162W mutations that were previously described in Ph 1 BCP-ALL cells. 24 These clinical and experimental observations suggest that Ikaros might play a more important role in B-cell development in human subjects than in mice. A detailed evaluation of bone marrow from the patients revealed that aberrant CLP development can cause a lack of peripheral B cells. Consistent with our data, Kuehn et al 9 described reduced pro-B cells and early precursors (CD19
1
CD34
1 and CD19
2 TdT 1 cells, respectively) in patients with germline IKZF1 mutations. Although the patients had reduced CLP counts, they had normal peripheral T-cell counts, which is consistent with the idea that T-cell lineage cells can directly develop from LMPPs beyond CLPs (see Fig E5) . 25 However, mouse studies have revealed that Ikaros influenced not only CLP development but also pre-B-cell development. The cells from patients with Ph 1 BCP-ALL with somatic IKZF1 alterations evade normal pre-B-cell differentiation. 26 The arresting of B cells in different stages of development might be due to differences in species or age. 20 We also speculate that IKZF1 mutations can affect pre-B-cell receptor signaling and the cell cycle in certain leukemic cells with pre-existing genetic changes. This is supported by the fact that IKZF1 alterations are found as secondary genetic changes in Ph 1 BCP-ALL cells. 27 The current and previous studies showed an increase in CD8 1 T cells and other T-cell dysfunctions in most of the patients. 9 These data implied that Ikaros might play some role in T-cell development, as well as B-cell development. Further investigation for T cells would be required.
Patient F.2 with the Y210C mutation had pancytopenia, resulting in hemorrhage just after birth. This is a similar phenotype reported in a patient with the Y210C mutation who underwent HSCT before hematologic recovery. 7 The Y210C mutation or possibly mutations affecting ZF4 might contribute to pancytopenia before and just after birth. Mouse models have shown phenotypic heterogeneity caused by individual mutations, especially those affecting individual ZFs, 6 and the differential requirements of Ikaros during fetal and adult hematopoiesis. 1 The residual DNA-binding activity was observed in Y210C Ikaros. Although normal pericentromeric localization of Y210C protein was found by using an artificially transfected cell line in the previous report, 9 our in vitro experiment demonstrated abnormal subcellular localization of Ikaros, as well as the case report of the Y210C mutation. 7 The difference among the reports might depend on use of a dominant normal allele or experimental procedure. In any case the Y210C mutation was considered to be a hypomorphic mutation, and it might be associated with a less severe clinical phenotype with the hematologic recovery, including B-cell counts.
In a previous study 2 of the 29 patients had BCP-ALL at 3 and 5 years of age. 9 However, there were not any patients who had neoplastic disorders, including BCP-ALL, in our study. The patients, especially those with p.N159S and p.R162W mutations, might have increased risk of BCP-ALL because the same somatic mutations were found in patients with Ph 1 BCP-ALL. 24 Four of 9 patients had autoimmune diseases, although only 1 presented with ITP in a previous study. 9 Heterozygous germline mutations in IKZF1 might be associated not only with B-cell deficiencies but also with autoimmune diseases. The clinical interest is that autoimmune disease can be presented even if dysgammaglobulinemia does not develop. Although genomewide association studies are providing support for the relationship between Ikaros and SLE, 8 its pathogenesis remains unclear. Further investigation is required.
In conclusion, we identified germline heterozygous IKZF1 mutations that caused dysgammaglobulinemia; hematologic abnormalities, including B-cell defects; and autoimmune diseases. This study provides new evidence for the involvement of IKZF1 in human hematopoiesis and immunology.
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Clinical implications: Heterozygous germline mutations in IKZF1 are associated with a novel human immunodeficiency characterized by B-cell deficiency. Peripheral B-cell deficiency can be caused by aberrant CLP development.
